ArticleKorean journal of radiology2026
Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.
Article in Korean journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo evaluate the feasibility, safety, and treatment outcomes of single-session whole-liver yttrium-90 (Y90) transarterial radioembolization (TARE) in patients with multifocal hepatocellular carcinoma (HCC). MATERIALS AND
methodsThis retrospective study included 37 patients (age, 23-86 years; median age, 60 years) with multifocal HCC (2-21 tumors; median, 9) and preserved liver function (Child-Pugh A) who underwent planned single-session whole-liver Y90 TARE between 2017 and 2024. Treatment was performed when no substantial liver parenchyma could be spared on pretreatment imaging and angiographic evaluation. Treatment planning was based on the findings of technetium-99m macroaggregated albumin single-photon emission computed tomography and partition-model dosimetry. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Overall survival, progression-free survival, and hepatic toxicity were also evaluated, with toxicity assessed on the basis of the occurrence of adverse events, Child-Pugh class change, and the development of ascites within 3-6 months.
resultsPatients were followed up for 1.4-49.0 months (median, 17.8 months). At 3 months, the objective response rate was 78.4%; the disease control rate was 94.6%; and complete response was noted in 11 patients (29.7%). Successful downstaging was achieved in 19 (51.4%) patients. The median overall survival was not reached, and the median progression-free survival was 23.5 months. The 2-year overall and progression-free survival rates were 78.3% and 46.8%, respectively. Eleven patients (29.7%) subsequently underwent surgery, including one resection and 10 living-donor liver transplantations. None of the patients showed grade 3 or 4 adverse events or radioembolization-induced liver disease. One patient with cirrhosis showed worsening of the Child-Pugh class with ascites.
conclusionSingle-session whole-liver Y90 TARE was feasible and showed acceptable hepatic safety in carefully selected patients with multifocal HCC and preserved liver function. It achieved high response and downstaging rates and may serve as a bridge to curative surgery in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.